Siyuan Cheng

Dr. Siyuan Cheng


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YXYaru Xu
Yaru Xu
YYYuqiu Yang
Yuqiu Yang
ZWZhaoning Wang
Zhaoning Wang
MSMartin Sjöström
Martin Sjöström
YJYuyin Jiang
Yuyin Jiang
PMPing Mu
Ping Mu
Cancer cells exhibit phenotypical plasticity and epigenetic reprogramming that allows them to evade lineage-dependent targeted treatments by adopting lineage plasticity. The underlying mechanisms by which cancer cells exploit the epigenetic regulatory machinery to acquire lineage plasticity and therapy resistance remain poorly understood. We identified zinc finger protein 397 (ZNF397) as a bona fide coactivator of the androgen receptor (AR), essential for the transcriptional program governing AR-driven luminal lineage. ZNF397 deficiency facilitates the transition of cancer cell from an AR-driven luminal lineage to a ten-eleven translocation 2 (TET2)-driven lineage plastic state, ultimately promoting resistance to therapies inhibiting AR signaling. Intriguingly, our findings indicate that a TET2 inhibitor can eliminate the resistance to AR-targeted therapies in ZNF397-deficient tumors. These insights uncover a novel mechanism through which prostate cancer acquires lineage plasticity via epigenetic rewiring and offer promising implications for clinical interventions designed to overcome therapy resistance dictated by lineage plasticity. Significance: This study reveals a bifurcated role of ZNF397, and a TET2–driven epigenetic mechanism regulating tumor lineage plasticity and therapy response in prostate cancer, enhances the understanding of drug resistance, and unveils a new therapeutic strategy for overcoming androgen receptor-targeted therapy resistance.

2 August 2024 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
SCSiyuan Cheng
Siyuan Cheng
LLLin Li
Lin Li
YYYunshin Yeh
Yunshin Yeh
YSYingli Shi
Yingli Shi
OFOmar Franco
Omar Franco
XYXiuping Yu
Xiuping Yu
Recent advancements in single-cell RNA sequencing (scRNAseq) have facilitated the discovery of previously unrecognized subtypes within prostate cancer (PCa), offering new insights into cancer heterogeneity and progression. In this study, we integrated scRNAseq data from multiple studies, comprising publicly available cohorts and data generated by our research team, and established the Human Prostate Single cell Atlas (HuPSA) and Mouse Prostate Single cell Atlas (MoPSA) datasets. Through comprehensive analysis, we identified two novel double-negative PCa populations: KRT7 cells characterized by elevated KRT7 expression and progenitor-like cells marked by SOX2 and FOXA2 expression, distinct from NEPCa, and displaying stem/progenitor features. Furthermore, HuPSA-based deconvolution re-classified human PCa specimens, validating the presence of these novel subtypes. We then developed a user-friendly web application, “HuPSA–MoPSA” (https://pcatools.shinyapps.io/HuPSA-MoPSA/), for visualizing gene expression across all newly established datasets. Our study provides comprehensive tools for PCa research and uncovers novel cancer subtypes that can inform clinical diagnosis and treatment strategies.

7 October 2022 in The Prostate
Verified
Journal Article
Closed access
SCSiyuan Cheng
Siyuan Cheng
XYXiuping Yu
Xiuping Yu

2 June 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ZDZhi Duan
Zhi Duan
MSMingchen Shi
Mingchen Shi
AKAnbarasu Kumaraswamy
Anbarasu Kumaraswamy
DLDong Lin
Dong Lin
DKDhruv Khokhani
Dhruv Khokhani
JAJoshi J. Alumkal
Joshi J. Alumkal
Lineage plasticity is recognized as a critical determinant of lethality and resistance to AR pathway inhibitors in prostate cancer. Lineage plasticity is a continuum, ranging from AR activity-low tumors, AR-null tumors that do not express a neuroendocrine prostate cancer (NEPC) program (i.e., double-negative prostate cancer [DNPC]), and AR-null NEPC tumors. Factors upregulated early in lineage plasticity are not well-characterized. The clarification of such factors is essential to identify tumors undergoing lineage plasticity or at risk of this occurring. Our integrative analysis of metastatic prostate cancer patient tumors, patient-derived xenografts, and cell models determined that PROX1 is upregulated early in the lineage plasticity continuum and progressively increases as tumors lose AR activity. We determined DNA methylation is a key regulator of PROX1 expression. PROX1 suppression in DNPC and NEPC reduces cell survival and impacts apoptosis and differentiation, demonstrating PROX1’s functional importance. PROX1 is not directly targetable with standard drug development approaches. However, affinity immunopurification demonstrated histone deacetylases (HDACs) are among the top PROX1-interacting proteins; HDAC inhibition depletes PROX1 and recapitulates PROX1 suppression in DNPC and NEPC. Altogether, our results suggest PROX1 promotes the emergence of lineage plasticity, and HDAC inhibition is a promising approach to treat tumors across the lineage plasticity continuum.

9 March 2024 in Cancer Letters
Verified
Journal Article
Closed access
SCSiyuan Cheng
Siyuan Cheng
LLLin Li
Lin Li
XYXiuping Yu
Xiuping Yu

8 March 2025 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
LLLin Li
Lin Li
KCKyung Hyun Cho
Kyung Hyun Cho
XYXiuping Yu
Xiuping Yu
SCSiyuan Cheng
Siyuan Cheng